Introduction: Predicting prognosis in cancer is complex. While traditional staging methods are useful, they do not fully account for the unique biology of each tumor. There is a growing need for biomarkers that capture this biological nuance, which is where molecular signatures like those involved in lactate metabolism (LMRGs) come into play. Methods: We conducted a structured narrative review of existing studies to investigate the link between LMRGs and patient survival. Our analysis spanned a wide array of cancers, from common types like breast and lung cancer to rarer forms such as sarcomas and gliomas, employing relevant keywords associated with lactate metabolism, gene signatures, and cancer prognosis. Results: Our synthesis of the data suggests a consistent trend: higher activity of lactate metabolism genes may be associated with more aggressive disease. Across many different cancers, this signature was reliably associated with worse outcomes for patients, including shorter survival times. Discussion: These findings suggest that LMRGs could be a valuable tool for dividing patients into more precise risk groups, potentially leading to more personalized treatment plans. However, moving this from research to the clinic will require overcoming hurdles like standardizing tests and proving its value in clinical trials. Conclusion: In summary, lactate metabolism genes may hold promise as a broadly applicable warning sign for aggressive cancer. Tapping into this metabolic "switch" could ultimately help doctors better predict outcomes and tailor treatments for their patients.
Mosaddeghi-Heris et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: